Short Interest in Black Titan Corp (NASDAQ:BTTC) Declines By 44.3%

Black Titan Corp (NASDAQ:BTTC) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,400 shares, a decline of 44.3% from the May 31st total of 4,312 shares. Based on an average daily trading volume, of 88,396 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.

Black Titan Trading Down 1.6%

Shares of BTTC opened at $0.74 on Friday. The company has a current ratio of 4.62, a quick ratio of 4.62 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $7.97 million, a price-to-earnings ratio of -0.25 and a beta of 1.21. The business’s 50 day simple moving average is $1.04. Black Titan has a 12-month low of $0.68 and a 12-month high of $39.00.

Black Titan (NASDAQ:BTTC) last announced its earnings results on Friday, June 12th. The company reported ($0.22) EPS for the quarter. The firm had revenue of $0.59 million for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new stake in shares of Black Titan in the fourth quarter valued at about $26,000. HRT Financial LP acquired a new position in Black Titan in the 4th quarter valued at about $28,000. Marex Group plc acquired a new position in Black Titan in the 4th quarter valued at about $84,000. Finally, Armistice Capital LLC purchased a new stake in Black Titan during the 4th quarter valued at approximately $840,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.